Refocus Group, Inc.

Refocus Group, Inc. is a medical device company based in Dallas, Texas, dedicated to researching and developing innovative treatments for human vision disorders, with a particular focus on presbyopia — the age-related loss of near vision that typically requires reading glasses. The company's flagship effort is the VisAbility™ Micro Insert System, an investigational device used in a procedure called the VisAbility Procedure. According to the company, VisAbility is designed to be the world's first binocular presbyopic treatment that works outside the visual axis, aiming to restore near vision in both eyes without affecting distance vision, so that patients can "See Young Again." The VisAbility Micro Insert System is currently an investigational medical device and is limited by United States law to investigational use. It has been studied in a clinical trial, and the company states that it was designed to help trial participants improve near vision in both eyes and reduce their need for reading glasses. Refocus Group positions itself as committed to providing the safest and most effective treatment for near vision correction, with a mission to be patients' go-to choice for near vision. The company is led by a leadership team organized into a Board of Directors, a Management Team, and a Clinical Team, whose members have experience across health care and medical device companies. Refocus Group maintains a corporate website at refocus-group.com, where it provides information about its mission, leadership, and the VisAbility technology, and invites visitors to bookmark the page to learn more upon FDA approval. VisAbility and the VisAbility logo are trademarks of Refocus Group, Inc.

Refocus Group, Inc. is a medical device company located in Dallas, Texas, United States. The company has focused its research and development efforts on innovative treatments for human vision disorders, particularly presbyopia. Its principal technology is the VisAbility™ Micro Insert System, described by the company as the world's first binocular presbyopic treatment that works outside the visual axis. The device is used in an innovative procedure called the VisAbility Procedure and is designed to restore near vision for patients with presbyopia without affecting their ability to see in the distance. As of the company's public communications, the VisAbility Micro Insert System remains an investigational medical device limited by United States law to investigational use, and the company has conducted a clinical trial in which the device was designed to help participants improve near vision in both eyes and reduce their need for reading glasses. Refocus Group states that it is committed to providing the safest and most effective treatment for near vision correction and maintains a corporate website with information about its mission, leadership team, and the VisAbility technology. The company's leadership is organized into a Board of Directors, a Management Team, and a Clinical Team, with members who have worked across health care and medical device companies. VisAbility and the VisAbility logo are trademarks of Refocus Group, Inc.

Developer of an investigational binocular presbyopic treatment that works outside the visual axis, aiming to reduce or eliminate the need for reading glasses.

• VisAbility™ Micro Insert System

  An investigational medical device used in the VisAbility Procedure, designed to restore near vision in patients with presbyopia without affecting distance vision. It is described as the world's first binocular presbyopic treatment that works outside the visual axis.

1. 1VisAbility Micro Insert Systemrefocus-group.com
2. 2About Us | VisAbility Micro Insert Systemrefocus-group.com
3. 3Our Mission | VisAbility Micro Insert Systemrefocus-group.com
4. 4Leadership Team | VisAbility Micro Insert Systemrefocus-group.com
5. 5Refocus Group (United States) - Wikidatawikidata.org